Clinical Trials Logo

Stomach Ulcer clinical trials

View clinical trials related to Stomach Ulcer.

Filter by:

NCT ID: NCT03214952 Completed - Clinical trials for Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis

Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Start date: March 1, 2016
Phase:
Study type: Observational

The purpose of this survey is to evaluate the safety and effectiveness of vonoprazan tablets in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in the routine clinical setting.

NCT ID: NCT03060746 Completed - Weight Loss Clinical Trials

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

Start date: February 14, 2017
Phase:
Study type: Observational

The primary objective is to obtain stool samples from pre-therapy subjects already undergoing evaluation for an H. pylori infection by upper esophagogastroduodenoscopy (EGD) and gastric biopsy.

NCT ID: NCT03060733 Completed - Weight Loss Clinical Trials

Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects

Start date: February 14, 2017
Phase:
Study type: Observational

The primary objective is to obtain stool samples from post-therapy subjects already undergoing evaluation for an H. pylori infection by upper esophagogastroduodenoscopy (EGD) and gastric biopsy.

NCT ID: NCT03050307 Completed - Gastric Ulcer Clinical Trials

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

Start date: April 17, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer.

NCT ID: NCT02761512 Completed - Gastric Ulcer Clinical Trials

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer

Start date: May 2016
Phase: Phase 3
Study type: Interventional

To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg capsule in gastric ulcer patients.

NCT ID: NCT02759224 Completed - Gastric Ulcer Clinical Trials

A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet

Start date: April 15, 2016
Phase: Phase 1
Study type: Interventional

An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual Tablets in Healthy Adult Volunteers

NCT ID: NCT02710994 Completed - Clinical trials for Gastroesophageal Reflux

Pharmacodynamics and Safety of CDFR0209

Start date: May 2014
Phase: Phase 1
Study type: Interventional

This is a randomized, open-label, two-way crossover study to investigate the pharmacodynamics(24 hour gastric pH) and the safety between repeated doses of CDFR0209 and Losec in Healthy Male Volunteers

NCT ID: NCT02423187 Completed - Gastric Ulcer Clinical Trials

Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin

Start date: March 17, 2015
Phase:
Study type: Observational

To investigate the safety and efficacy of long-term combination therapy with rabeprazole and low-dose aspirin.

NCT ID: NCT02299687 Completed - Stomach Ulcer Clinical Trials

Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole

Start date: September 2014
Phase: Phase 1
Study type: Interventional

A clinical trial to investigate the influence of CYP2C19 polymorphism on pharmacokinetic/pharmacodynamic characteristics of omeprazole in healthy Korean volunteers

NCT ID: NCT02219529 Completed - Chronic Gastritis Clinical Trials

Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases

MCE
Start date: August 2014
Phase: Phase 3
Study type: Interventional

A new Magnetic-controlled Capsule Endoscopy (MCE) was developed by ANKON and got SFDA's approval in China in 2013. It has recently been evaluated to compare the diagnostic accuracy of MCE with that of standard gastroscopy for gastric diseases in 70 patients with encouraging results (In Press). To further testify the diagnostic accuracy of MCE for both the diffuse and focal diseases in stomach, we performed this single-blinded multi-center prospective study compared MCE with gastroscopy in patients with gastric symptoms and indication for upper GI Endoscopy.